BioLineRx (BLRX) Cash from Investing Activities (2013 - 2025)

BioLineRx's Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$337000.0 for Q4 2025.

• In Q4 2025, Cash from Investing Activities fell 103.02% year-over-year to -$337000.0; the TTM figure through Dec 2025 stood at -$8.5 million (down 129.09% YoY), while the FY2025 annual figure was -$8.5 million, down 129.09% from the prior year.
• Cash from Investing Activities was -$337000.0 for Q4 2025 at BioLineRx, down from $3.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $16.7 million in Q1 2024 to a low of -$36.3 million in Q1 2021.
• Historically, Cash from Investing Activities has averaged -$597250.0 across 5 years, with a median of $3.8 million in 2022.
• Biggest YoY gain for Cash from Investing Activities was 267.16% in 2022; the steepest drop was 37437.5% in 2022.
• A 5-year view of Cash from Investing Activities shows it stood at $4.0 million in 2021, then fell by 3.4% to $3.9 million in 2022, then plunged by 628.09% to -$20.4 million in 2023, then soared by 154.7% to $11.2 million in 2024, then plunged by 103.02% to -$337000.0 in 2025.
• The last three Cash from Investing Activities figures came in at -$337000.0 (Q4 2025), $3.7 million (Q3 2025), and -$3.7 million (Q2 2025), per Business Quant data.